Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BMY NASDAQ:IOVA NYSE:MRK NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMYBristol Myers Squibb$59.51-0.1%$58.46$42.52▼$62.89$121.61B0.2610.45 million shs6.49 million shsIOVAIovance Biotherapeutics$4.11+11.1%$3.63$1.66▼$5.63$1.84B0.6914.75 million shs23.07 million shsMRKMerck & Co., Inc.$122.55+5.8%$115.92$75.40▼$125.14$302.33B0.188.53 million shs14.75 million shsNVSNovartis$152.14+0.3%$150.02$111.06▼$170.46$290.06B0.461.35 million shs1.41 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMYBristol Myers Squibb-0.13%+4.32%+1.14%-1.90%+26.69%IOVAIovance Biotherapeutics+11.08%+19.13%+16.43%+43.21%+134.19%MRKMerck & Co., Inc.+5.78%+10.05%+8.58%+0.41%+59.38%NVSNovartis+0.20%+2.80%+3.24%-6.52%+34.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMYBristol Myers Squibb$59.51-0.1%$58.46$42.52▼$62.89$121.61B0.2610.45 million shs6.49 million shsIOVAIovance Biotherapeutics$4.11+11.1%$3.63$1.66▼$5.63$1.84B0.6914.75 million shs23.07 million shsMRKMerck & Co., Inc.$122.55+5.8%$115.92$75.40▼$125.14$302.33B0.188.53 million shs14.75 million shsNVSNovartis$152.14+0.3%$150.02$111.06▼$170.46$290.06B0.461.35 million shs1.41 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMYBristol Myers Squibb-0.13%+4.32%+1.14%-1.90%+26.69%IOVAIovance Biotherapeutics+11.08%+19.13%+16.43%+43.21%+134.19%MRKMerck & Co., Inc.+5.78%+10.05%+8.58%+0.41%+59.38%NVSNovartis+0.20%+2.80%+3.24%-6.52%+34.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMYBristol Myers Squibb 2.37Hold$61.313.04% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.43105.07% UpsideMRKMerck & Co., Inc. 2.68Moderate Buy$128.184.59% UpsideNVSNovartis 2.31Hold$141.20-7.19% DownsideCurrent Analyst Ratings BreakdownLatest IOVA, NVS, BMY, and MRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.005/6/2026MRKMerck & Co., Inc. CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$125.005/1/2026MRKMerck & Co., Inc. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/1/2026BMYBristol Myers Squibb CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/1/2026MRKMerck & Co., Inc. Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $145.004/29/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)4/13/2026MRKMerck & Co., Inc. UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$130.00 ➝ $145.004/10/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.004/9/2026BMYBristol Myers Squibb Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $67.004/8/2026BMYBristol Myers Squibb Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$45.00 ➝ $54.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMYBristol Myers Squibb$48.19B2.52$8.13 per share7.32$9.84 per share6.05IOVAIovance Biotherapeutics$285.61M6.43N/AN/A$1.62 per share2.54MRKMerck & Co., Inc.$65.77B4.60$12.07 per share10.15$18.60 per share6.59NVSNovartis$56.58B5.13$10.77 per share14.13$20.40 per share7.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMYBristol Myers Squibb$7.05B$3.5616.719.800.1715.01%64.87%13.16%7/30/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)MRKMerck & Co., Inc.$18.25B$3.5534.5212.532.6113.59%27.55%10.73%8/4/2026 (Estimated)NVSNovartis$13.98B$6.9821.8015.482.6724.87%38.82%15.16%7/21/2026 (Estimated)Latest IOVA, NVS, BMY, and MRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million4/30/2026Q1 2026BMYBristol Myers Squibb$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billion4/30/2026Q1 2026MRKMerck & Co., Inc.-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion2/24/2026Q4 2025IOVAIovance Biotherapeutics-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMYBristol Myers Squibb$2.524.23%+1.61%70.79%17 YearsIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.402.77%+5.75%95.77%14 YearsNVSNovartis$3.082.02%+5.28%44.13%N/ALatest IOVA, NVS, BMY, and MRK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/2/2026BMYBristol Myers Squibbquarterly$0.634.23%4/2/20264/2/20265/1/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMYBristol Myers Squibb2.101.421.28IOVAIovance BiotherapeuticsN/A3.603.15MRKMerck & Co., Inc.1.021.301.06NVSNovartis0.960.850.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMYBristol Myers Squibb76.41%IOVAIovance Biotherapeutics77.03%MRKMerck & Co., Inc.76.07%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipBMYBristol Myers Squibb0.05%IOVAIovance Biotherapeutics7.80%MRKMerck & Co., Inc.0.17%NVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMYBristol Myers Squibb32,5002.04 billion2.04 billionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableMRKMerck & Co., Inc.75,0002.47 billion2.47 billionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableIOVA, NVS, BMY, and MRK HeadlinesRecent News About These CompaniesNovartis (NVS) Positioned for Growth Through Transformative InnovationsMay 21 at 5:47 PM | finance.yahoo.comNovartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHAMay 21 at 1:15 AM | globenewswire.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18, 2026 | zacks.comUS Supreme Court rebuffs pharma challenge to Biden-era drug priceMay 18, 2026 | reuters.comAs U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade (NVS)...May 18, 2026 | marketbeat.comNovartis International AG: Novartis tender offer for Advanced Accelerator Applications commencesMay 16, 2026 | finanznachrichten.deImplied Volatility Surging for Novartis Stock OptionsMay 13, 2026 | zacks.comNovartis breaks ground on US radioligand therapy siteMay 12, 2026 | pmlive.comPNovartis AG (NVS) Expands U.S. Manufacturing Footprint with New Texas SiteMay 11, 2026 | insidermonkey.comQ2 Earnings Forecast for Novartis Issued By Zacks ResearchMay 11, 2026 | marketbeat.comNewEdge Wealth LLC Has $69.67 Million Stock Position in Novartis AG $NVSMay 10, 2026 | marketbeat.comNovartis AG (NYSE:NVS) Receives Average Recommendation of "Hold" from BrokeragesMay 10, 2026 | marketbeat.comFY2027 EPS Estimates for Novartis Lifted by Erste Group BankMay 8, 2026 | marketbeat.comNovartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilitiesMay 7, 2026 | globenewswire.comThis small biotech — taking on AbbVie, Novartis and Sanofi — just catapulted into a breakoutMay 6, 2026 | msn.comPrincipal Financial Group Inc. Reduces Holdings in Novartis AG $NVSMay 6, 2026 | marketbeat.comNew Bill: Representative Kathy Castor introduces H.R. 8651: Advancing Safe Medications for Moms and Babies Act of 2026May 5, 2026 | quiverquant.comQNovartis to cut 220 jobs as it closes German siteMay 5, 2026 | reuters.comQRG Capital Management Inc. Boosts Stock Holdings in Novartis AG $NVSMay 5, 2026 | marketbeat.comNovartis AG $NVS Shares Purchased by Truist Financial CorpMay 5, 2026 | marketbeat.comTriasima Portfolio Management inc. Acquires 32,620 Shares of Novartis AG $NVSMay 4, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOVA, NVS, BMY, and MRK Company DescriptionsBristol Myers Squibb NYSE:BMY$59.50 -0.05 (-0.08%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$59.40 -0.11 (-0.18%) As of 05/22/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.Iovance Biotherapeutics NASDAQ:IOVA$4.11 +0.41 (+11.08%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.06 -0.05 (-1.22%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Merck & Co., Inc. NYSE:MRK$122.55 +6.67 (+5.76%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$122.52 -0.02 (-0.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Novartis NYSE:NVS$152.14 +0.38 (+0.25%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$152.00 -0.14 (-0.09%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
